Manufacturer of amivantamab

Amivantamab (amivantamab) is a breakthrough bispecific antibody in the treatment of non-small cell lung cancer, and the manufacturer behind it has attracted much attention. This drug is developed and produced by Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, a world-renowned pharmaceutical company. Janssen has profound experience in oncology, immunology and biologics research and development, and evantumumab is one of the company's representative achievements in the field of precision medicine and targeted therapy.

Janssen PharmaceuticalsIn 2021, evantumumab was the first to be approved in the United States, making it the first specialized drug for non-small cell lung cancer with EGFR exon20 insertion mutations. Since then, the drug has been gradually approved for marketing in the EU and China, further expanding global accessibility. As a bispecific antibody, evantumumab involves complex protein engineering and quality control during the design and production process. Janssen has ensured a stable supply of the drug with its mature R&D platform and production capabilities.

Currently, evantuzumab sold in the global market comes from Janssen’s original research product, and there is no generic version yet. This means that the price and supply channels of drugs are completely in the hands of the original manufacturers, which also explains why there is a large price difference between domestic and overseas markets. Janssen not only provides production guarantees, but also actively promotes the exploration of combination use of the drug in clinical research, such as combining it with immune checkpoint inhibitors or other targeted drugs, in order to further expand the efficacy and scope of indications.

As an important subsidiary of Johnson & Johnson, Janssen has a complete global layout and can quickly bring innovative drugs to the market. This is also an important reason why evantumumab can quickly enter clinical practice in many countries. For patients and doctors, identifying the manufacturer not only helps to understand the research and development background of the drug, but also provides a reference for possible future development and price reduction of generic drugs.

Reference materials:https://www.rybrevant.com/